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ABSTRACT 
Background:  
Vascular Endothelial Growth Factor A (VEGF-A) is a fundamental regulator of 
tumour angiogenesis. Tissue VEGF-A can be assessed by immunohistochemistry 
using antibodies against VEGF-A on formalin fixed paraffin embedded tissue (FFPE) 
sections. 
Aim and Objectives: 
To study the expression of Vascular Endothelial Growth Factor A (VEGF-A) in 
tissues of Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma by 
Immunohistochemistry (IHC). 
Material and Methods:   
Immunohistochemical detection of VEGF was done using polyclonal antibody and 
Poly Excel HRP/DAB chromogen detection system on 40 samples, which included 
Oral Submucous Fibrosis (OSMF-10 cases),Oral Squamous Cell Carcinoma (OSCC-
20 cases) and the expression was compared with that of normal mucosa (10 cases). 
The positive control used for VEGF was human normal kidney.  
Results:   
The pattern of VEGF staining in all the cases (N=40) was cytoplasmic. All the cases 
of OSCC and OSMF expressed 100% positivity for VEGF expression and 70% of 
normal mucosa cases expressed positivity. Positive cytoplasmic VEGF in OSMF was 
seen in basal and suprabasal layers and in OSCC was seen in tumour nest cells. 
Periphery cells of cancer nests were more heavily stained than the central cells of 
cancer nests. Stromal staining was excluded for recording of positive expression. 
 
 
Conclusion: 
Thus, there is increased expression of VEGF in Oral Submucous Fibrosis and Oral 
Squamous Cell Carcinoma when compared to that of normal mucosa suggesting that 
VEGF may be used as a useful marker in the assessment of angiogenesis in OSMF 
and invasive OSCC. The analysis of VEGF expression could also help in early 
detection of tumours and thereby reducing the mortality and morbidity of oral cancer. 
Key words: VEGF, OSMF , OSCC 
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                                                                    Introduction 
Introduction 
  
Cancer is the third cause of death in developing countries. Oral and 
pharyngeal cancer is the sixth most common cancer worldwide with an annual rate of 
27 500 for the oral cavity and 130 300 for pharyngeal cancer excluding the 
nasopharyx; two thirds of this rate was reported to be in developing countries1. Oral 
Squamous Cell Carcinoma (OSCC) accounts for more than 90% of all the oral 
cancers, representing 6% of all cancers 2.  It is the most frequent malignant tumour in 
the oral cavity and the eighth most common cancer worldwide2.  In India, it is most 
common among males and the third most common among females3. 
Oral squamous cell carcinoma remains a serious problem of oral health 
worldwide. Despite attempts and approaches to intervene the disease, aiming at 
detecting the premalignant lesions and Oral Squamous Cell Carcinoma (OSCC) at the 
earliest stage and treating patients with several modalities, the overall survival rate of 
patients with OSCC improves only slightly. In order to provide preventive and 
prognostic measures for patients with OSCC, molecular biological markers of OSCC 
have been extensively studied and developed. Yet, there has been no reliable marker 
universally accepted for OSCC so far4. 
Oral Submucous Fibrosis (OSMF) was first described in 1952 as a chronic, 
progressive,   precancerous condition of the oral mucosa, associated with areca nut 
chewing, widely prevalent in the Indian subcontinent and South East Asia. Oral 
Submucous Fibrosis (OSMF) is characterised by pallor, burning sensation of the oral 
mucosa, progressive, irreversible fibrosis limiting mouth opening that causes  
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difficulty in speaking and swallowing. The World Health Organisation (WHO) 
defined OSMF as “a slowly progressive disease in which the fibrous bands form in 
the oral mucosa, ultimately leading to severe restriction of movement of the mouth, 
including the tongue5.  
Oral carcinogenesis is considered to be a sequential and multistep process that 
is mediated by the deregulation of crucial molecular pathways, among which 
angiogenesis has long been considered one of the most important mechanisms 
involved in the biology of cancer6. Oral tissues exhibit classical stages of disease 
progression (normal, mild/moderate/severe dysplasia and carcinoma). Clinical studies 
suggest that 10-20% of all dysplastic oral lesions progress to carcinoma. Although it 
is not possible to determine whether a particular dysplastic lesion will progress to 
carcinoma, such clinical data may indicate that a comparison of normal mucosa, 
dysplastic lesions and carcinoma in oral tissues may be used as a model to study 
tumour progression7. 
Angiogenesis is the process of new blood vessel formation from pre-existing 
ones and is crucial for normal development and growth of the organism. Excessive or 
deficient angiogenesis is crucial in different pathological conditions such as tumour 
growth, progression and spread8. This biological process is complex and mediated by 
several stimulators4. Since angiogenesis increases with disease progression in several 
malignant tumours including malignant melanoma, breast cancer and OSCC, 
potentially, angiogenesis can be used as an independent prognostic marker in human 
cancers4. 
 
Introduction 
  
Vascular Endothelial Growth Factor (VEGF) is a vital regulator of vascular 
development during vasculogenesis and angiogenesis. VEGF is a type of 
glycoprotein, which has both angiogenic and mitogenic factors, as well as vascular  
permeability factor (VPF), thus enhancing activity in endothelial cells. VEGF family 
includes VEGF-A, B, C and D, as well as placenta growth factor9.  
VEGF-A was first identified by Dvorak et al., as a vascular permeability –
inducing factor secreted by tumour cells and thus referred to as vascular permeability 
factor (VPF)10. In tumour angiogenesis, VEGF A is produced by neoplastic cells and 
stroma, including fibroblasts and inflammatory cells. High VEGF A expression 
stimulates new blood vessel formation from pre-existing vessels, whereas lower 
VEGF A expression induces endothelial cell apoptosis10.  
Literature has evidence of the role of VEGF- A in OSCC and OSMF but 
limited knowledge is available from India.  
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Aim and Objectives 
  
AIM: 
 
To study the expression of Vascular Endothelial Growth Factor A (VEGF-A) 
in tissues of Oral Submucous Fibrosis (OSMF) and Oral Squamous Cell Carcinoma 
(OSCC) by Immunohistochemistry (IHC). 
OBJECTIVES: 
To investigate the extent of VEGF-A expression in tissues of Oral Submucous 
Fibrosis and Oral Squamous Cell Carcinoma by Immunohistochemistry. 
HYPOTHESIS (NULL): 
There is no difference in the expression of VEGF- A in Oral Submucous 
Fibrosis and Oral Squamous Cell Carcinoma when compared to normal mucosa. 
STUDY SETTING: 
The study was conducted in the Department of Oral and Maxillofacial 
Pathology, Ragas Dental College and Hospital, Chennai, using archival blocks of Oral 
Submucous Fibrosis, Oral Squamous Cell Carcinoma and normal mucosa using 
immunohistochemistry. All related depersonalised records from archives were 
gathered. 
STUDY SUBJECTS:  
The study material comprised of 40 formalin-fixed, paraffin embedded tissue 
specimens.  The samples were divided into 3 groups namely: Group I, Group II and 
Group III.  
Group I: 15 normal oral mucosal tissue specimens.  
Group II: 15 histopathologically confirmed OSMF tissue specimens. 
Group III: 15 histopathologically confirmed OSCC tissue specimens 
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Materials and Methods 
  
 
1) Tissue samples of normal mucosa, Oral Submucous Fibrosis and Oral Squamous 
Cell Carcinoma were taken from the archival blocks. 
2) A detailed case history including patient’s age, gender, past medical and dental 
history, history of drugs and trauma was taken from records for controls. 
3) Incisional biopsy was taken when patients were undergoing minor surgery for 
extraction of impacted teeth with no pericoronitis or inflammation at the lesional site 
for normal oral mucosa. 
4) The tissue biopsied was immediately transferred to 10% buffered formalin. 
5) After adequate fixation, tissues were embedded in paraffin. 
6) From the paraffin embedded blocks 5 micron thick sections were cut and used for 
routine hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) 
staining. 
8) Positive control for VEGF-A was a section of normal human kidney tissue77 
(previously known positive case for VEGF-A). 
 
HEMATOXYLIN AND EOSIN (H& E) STAINING: 
REAGENTS 
Harris hematoxylin 
1% acid alcohol 
Eosin 
Xylene 
Alcohol 
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 The slides were dewaxed in xylene and hydrated through grades of alcohol to 
water. The sections on the slides were flooded with Harris’s hematoxylin for 5 
minutes. The slides were washed in running tap water for 5 minutes. The slides were 
differentiated in 1% acid alcohol for 5 minutes. The slides were washed well in 
running tap water for 5 minutes. The tissue sections on the slides were then stained in 
eosin for 30 seconds. The slides were washed in running tap water for 1 minute. The 
slides were then dehydrated through alcohol, cleared, mounted and viewed under light 
microscope. 
 
IMMUNOHISTOCHEMICAL  STAINING (VEGF-A): 
 
Armamentarium: 
                               Microtome 
                               Autoclave 
                               Hot air oven 
                               Slide warmer 
                               Couplin jars 
                               Measuring jar 
                               Weighing machine 
                               APES coated slides (Amino propyl triethoxysilane) 
                               Slide box 
                                
                             Materials and Methods                                
  
                                Aluminium foil 
    
                                Micro-pipettes 
                               Toothed forceps 
                               Electronic timer 
                               Beakers 
                               Rectangular steel tray with glass rods 
                               Sterile gauze 
                               Cover slips 
                               Light microscope 
 
REAGENTS USED 
                             1) APES (3 amino propyl tri ethoxysilane) 
                             2) 1 N sodium hydroxide 
                             3) 1 N Hydrochloric acid 
                             4) Tris EDTA (Ethylene Diamine Tetra Acetate )buffer 
                             5) Tris buffered Saline  
                             6) 3% Hydrogen peroxide 
                                      7) Distilled water 
                             8) Hematoxylin 
                             9) Absolute alcohol (Isopropyl alcohol) 
                            10) Xylene 
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ANTIBODIES USED: 
 
1) Primary antibody –  Anti-VEGF-A mouse monoclonal antibody, Clone: VG1,  
                                  Prediluted(1:100), CAT NO-PM175 (Pathnsitu) 
2) Secondary antibody-Poly Excel-HRP Micro polymer IHC Detection system,  
                                 CAT NO- OSH001 (Pathnsitu) 
 
PREPARATION OF PARAFFIN SECTIONS 
After the slides were dried, tissue sections of 5 micron thickness were made in 
a rotary manual microtome. The ribbons of tissue section were transferred onto the 
APES coated slides from the tissue float bath such that two tissue bits come on to 
each slide with a gap in between. One of the tissue sections towards the frosted end of 
the slide was labelled negative to which negative serum, the secondary and the 
chromogen were added and the tissue section away from the frosted side is the 
positive to which the primary antibody, secondary antibody and chromogen were 
added. 
 
IHC PROCEDURE 
The slides with tissue sections were treated with three changes of xylene to remove 
paraffin wax. They were put in descending grades of alcohol and then rehydrated with 
water. Circles were drawn using a diamond marker around the tissues, so that the 
antibodies added later on do not spread and are restricted to the circle. The slides were  
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transferred to TRIS EDTA buffer of pH  9 and steamed in pressure cooker for antigen 
retrieval at 15 lbs pressure for 15 minutes. Slides were then treated with 3 % 
polyexcel hydrogen peroxide for 7 minutes to quench endogenous peroxidase activity 
of cells that would result in non-specific staining then the slides were dipped in TRIS 
buffered saline with Tween 20 for 6 minutes. The slides were wiped carefully without 
touching the tissue section. The sections were incubated overnight at 4 degree celsius 
with primary rabbit polyclonal antibody (VG-1; 1:100 dilution) raised against a 20 
amino acid synthetic peptide of human VEGF-A (Pathnsitu). Primary antibody was 
detected using super sensitive polymer-HRP IHC detection system (Pathnsitu). After  
thorough washing with Tris buffered saline (TBS; pH 7.4) sections were treated with 
super enhancer for 20 min at room temperature followed by incubation with  
Poly - HRP reagent for 30 min at room temperature. After three washes with TBS, 
substrate DAB (3, 30 - diaminobenzidine tetrahydrochloride) was applied to the 
sections for 5–10 min in the dark. Slides were then washed in distilled water to 
remove excess chromogen counterstained with hematoxylin, dehydrated with ethanol 
and xylene and mounted permanently with DPX. The slides were then observed under 
the microscope. 
 
POSITIVE AND NEGATIVE CONTROL: 
Section of normal human kidney tissue that was previously shown to be positive for 
VEGF was used as positive control. Negative control sections were processed by 
omitting primary antibody77. 
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IHC PROCEDURE: 
1. APES coated slides with 2 paraffin embedded tissue placed in warming table 
2. Placed in xylene twice (5 minutes each) 
3. Placed in 100% isopropanol (5 minutes) 
4. Placed in 90% isopropanol (5 minutes) 
5. Placed in 70% isopropanol (5 minutes) 
6. Washed in distilled water (2 minutes each) 
7. Keep in TRIS EDTA buffer at pH 9 for antigen retrieval 
8. Placed in 3% hydrogen peroxide (7 minutes) 
9. Washed with Tris buffer (2-3 minutes) 
10. Primary antibody added and incubated (1 hour 30 minutes) 
11. Washed in Tris buffer (2-3 minutes)  
12. Poly excel target binder reagent added and incubated (12 minutes) 
13. Washed in Tris buffer (2-3 minutes) 
14. Poly excel HRP added and incubated (12 minutes) 
15. Washed slides in Tris buffer (2-3 minutes) 
16. DAB added and incubated in an enclosed in hydrated container (3 minutes) 
17. Washed in Tris thrice (2-3 minutes) 
18. Stained with Harris Hematoxylin (20 seconds) 
19. Washed in tap water 
20. Placed in 70% alcohol (1 minute) 
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21. Placed in 100% alcohol (1 minute) 
22. Placed in xylene (1 dip) 
23. Slides to be mounted using DPX 
24. Slides to be observed under the LM and graded 
 
 CRITERIA FOR EVALUATION OF STAINING: 
 
Evaluation of H & E sections: 
•The H&E stained sections were thoroughly examined.
•Oral Squamous Cell Carcinomas were graded as well differentiated, moderately  
   differentiated and poorly differentiated12. 
Evaluation for IHC: 
•Corresponding sections as examined by H & E were stained by IHC to detect    
  VEGF-A expression. 
•To all these sections the VEGF-A antibody and the tris buffer saline were added   
   based on the IHC protocol for the VEGF-A antibody. 
•The positive control was a section of normal human kidney tissue that was  
   previously shown to be positive for VEGF77. 
•VEGF expression was evaluated as brown cytoplasmic staining in the vessels, in the  
   cells of inflammatory infiltrate (mainly lymphocytes, plasma cells, neutrophils), in  
   stromal cells (fibroblasts) and epithelial cells12. 

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•Percentage of positive cells were also counted in each case and it was categorised as  
   0= no expression; 1+ = <25% of cells positive; 2+ = 25% to 50%; 3+ = >50% of  
   cells positive13. 
•Connective tissue was also examined in all the lesions. 
•The Mean Labelling Index (MLI) for all the positive groups were 
   calculated using the formula13: 
                                             Number of positive cells X 100 
                                                     Total number of cells 
TISSUE LOCALISATION: 
Epithelial cells that exhibited brown cytoplasmic staining were counted as 
positive for expression of VEGF-A. The sections were initially scanned at low power. 
For sections that showed heterogeneous staining, the predominant pattern was taken 
into account for scoring. At least four high-power fields were then chosen randomly, 
and 1000 cells were counted for each case2. 
 
CELLULAR LOCALIZATION OF STAIN: 
Brown colour of VEGF staining was seen as cytoplasmic or membranous 
granules. The stained slides were screened, examined systematically for VEGF- A 
expression in cytoplasmic portion and wall of the epithelial cell12. 
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INTENSITY OF STAINING 
  
The VEGF-A intensity was analysed in the study groups. Each case was 
graded as (-) nil or absence of stain, (+) mild, (++) moderate and (+++) intensively 
stained based on the intensity of staining taken up by the tissue as observed by two 
blinded observers independently with respect to positive control7. 
 
STATISTICAL ANALYSIS  
Data were entered and analyzed using SPSSTM software (version 20.0). 
Pearson’s Chi-square test was done to compare intensity of staining between the 
groups. p value ≤ 0.05 was considered statistically significant. 
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Angiogenesis is a complex multi-step process involving extensive interplay 
between cells, soluble factors, and extracellular matrix (ECM) components. Four 
distinct sequential steps in angiogenesis include: (1) degradation of basement 
membrane by proteases; (2) migration of endothelial cells (ECs) into the interstitial 
space and sprouting; (3) ECs proliferation at the migrating tip; (4) lumen formation, 
generation of new basement membrane with the recruitment of pericyte, formation of 
anastomoses and finally blood flow14. 
Factors involved in tumour angiogenesis  
Vascular endothelial growth factor and receptors 
Vascular endothelial growth factor (VEGF), also known as Vascular 
permeability factor (VPF), is a heparin-binding angiogenic growth factor, and is 
highly expressed in various types of tumors. It may increase ECs permeability by 
enhancing the activity of vesicular - vacuolar organelles, clustered vesicles in ECs 
lining small vessels that facilitate transport of metabolites between luminal and 
abluminal plasma membranes. In addition, recent studies have shown that VEGF 
enhances ECs permeability by activating PKB/Akt, endothelial nitric oxide synthase 
(eNOS), and MAP kinase dependent pathways using human umbilical vein 
endothelial cell. Increased vascular permeability may allow the extravasation of 
plasma proteins and formation of ECM favourable to endothelial and stromal cell 
migration14. 
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Other factors involved in tumour angiogenesis 
Fibroblast growth factors 
Angiopoietins 
Transforming growth factor –beta 
Interleukin -8 
Matrix metalloproteinase-2 
Oncogenes and tumour suppressor genes14. 
 
The Biology of Vascular Endothelial Growth Factor(VEGF) 
The biological activities of VEGF 
The development of vascular supply is a fundamental requirement for organ 
development and differentiation during embryogenesis. Vascular development occurs 
in several stages, beginning with the assembly of a vessel plexus from single cell 
precursors (vasculogenesis).The vascular plexus then undergoes modification by 
sprouting growth and remodelling (angiogenesis), followed by recruitment of vessels 
into target tissues. Finally, new vessels differentiate according to the specific needs of 
the tissue15. 
Vascular endothelial growth factor (VEGF), also known as VEGF-A, is a 
potent angiogenic cytokine involved in every stage of vascular development. The 
multiple roles of VEGF are based on its ability to induce various responses by 
endothelial cells during vascular development, including cell proliferation, migration,  
 
 
Review of literature 
 
specialisation and survival. During vascular morphogenesis VEGF promotes the 
differentiation of cell precursors into endothelial cells and their early assembly into a 
primary vascular plexus15. It then induces and guides angiogenic sprouting to expand 
the primary plexus and vascularise growing tissues. VEGF then aids in endothelial 
cell proliferation, pericyte coverage and the distribution of arteries and veins. In 
addition, VEGF induces vasodilation and increases permeability of vascular beds15. 
VEGF receptors and co-receptors 
VEGF binds to two receptors, VEGF receptor-1(VEGFR-1) and VEGF 
receptor-2 (VEGFR-2). All VEGF isoforms bind to VEGFR-1 and VEGFR-2 as well 
as interacting with a family of co-receptors, the neutropilins. Activation of VEGFR-1 
promotes endothelial cell migration but does not induce cell proliferation.VEGFR-1 
may also act as a decoy receptor that regulates overall VEGF concentration receptor  
by binding VEGF and preventing its association with VEGFR-2. VEGFR-2 is the 
major mediator of endothelial cell mitogenesis, proliferation and survival15. 
Regulation of VEGF gene expression 
VEGF gene transcription is induced by exposure to low oxygen tension in a 
variety of circumstances like embryonic organ formation or tumour growth. 
Cytokines and growth factors that do not stimulate angiogenesis directly can regulate 
angiogenesis by modulating VEGF gene expression15. Oncogenic mutation or 
inactivation of tumour suppressor genes can also result in induction of VEGF gene 
expression16.  
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                                       ORAL SUBMUCOUS FIBROSIS 
Oral Submucous Fibrosis is a chronic, insidious disease that affects the lamina propria 
of the oral mucosa and as the disease advances, it involves tissues deeper in the 
submucosa of the oral cavity with resulting loss of fibroelasticity. The disease 
manifests with blanching and stiffening of the oral mucosa, leading to limitation in 
opening of the mouth17. 
OSMF was first described in 1952 by Schwartz among five Indian females living in 
Kenya and he coined the term atrophica idiopathica mucosae oris17. A 1953 study 
from Bombay named the condition OSMF, defining its histologic characteristics5. 
World Health Organisation (WHO) defined OSMF as “a slowly progressive disease in 
which the fibrous bands form in the oral mucosa, ultimately leading to severe 
restriction of movement of the mouth, including the tongue”5. 
ETIOLOGY 
Until about a decade and half ago, the etiology of the disease was thought to 
be multifactorial and several agents had been reported including local irritants 
(chillies), nutritional deficiency and autoimmune disease. However, more recent 
studies have confirmed areca nut as the major risk factor among people who have 
genetic predisposition to the disease17. Areca nut, is the fourth most commonly abused 
substance in the world (following nicotine, ethanol and caffeine). 10-20% of the 
world population chews areca nut in some form and more than 200 million people 
chew betel quid worldwide18. 
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MECHANISMS OF THE PATHOGENESIS OF ORAL SUBMUCOUS 
FIBROSIS 
Changes in the extracellular matrix 
Arecoline appears to be involved in the pathogenesis and increased collagen 
formation. Involvement of the connective tissue growth factor (CTGF) in fibrosis in 
human tissues is well established. Deng et al., showed expression of CTGF in OSMF 
fibroblasts and endothelial cells in all of the OSMF cases included in their study. 
Their in vitro data showed that arecoline stimulated CTGF production in 
buccal mucosal fibroblasts through the generation of reactive oxygen species (ROS) 
and by the activation of NF-kappa B, JNK and p38 MAPK pathways which are 
strongly activated by ROS. Significance of ROS in the pathogenesis and malignant 
transformation of OSMF is well known19. 
Arecoline influences the deposition of extracellular matrix (ECM) by 
increasing the production of tissue inhibitor of metalloproteinase -1 (TIMP-1) and the 
effect is enhanced when fibroblasts are co-cultured with keratinocytes. These data 
suggested that an interaction of oral keratinocytes and fibroblasts may play an 
important role in the pathogenesis of OSMF20. 
Reduced vascularity is another hallmark of OSMF. The antiproliferative and 
cytotoxic effects of arecoline are possibly associated with alteration of specific cell 
cycle regulatory proteins. Therefore, it is reasonable to suggest that the endothelial  
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damage leading to impairement of vascular function contribute to the pathogenesis of 
OSMF17. 
Copper and the related structural changes of collagen 
The role of copper in the pathogenesis of OSMF is due to the discovery of 
high copper content in arecanut. Copper dependent enzyme lysyl oxidase is critical 
for collagen cross-linking and organisation of ECM17. 
Morphologic features of ECM remodelling in OSMF 
Histopathologic evidence shows ECM remodelling with the progression of the 
disease. In the early stages of OSMF, overexpression of tenascin, perlecan, 
fibronectin and collagen type 3 may be found in the lamina propria and submucosa 
and extensive and irregular deposits of elastin have been found around muscle fibres 
in the intermediate stage, together with these molecules. In the advanced stage of 
OSMF, collagen type 1 appears to dominate the ECM. Difficulty in mouth opening 
may be related to loss of various ECM molecules, such as elastin, replacement of 
muscle by type 1 collagen17. 
Inflammatory cytokines and growth factors 
Upregulation of various cytokines namely transforming growth factor 
(TGF)β1,  (TGF)β1, thrombospondin 1, secreted phosphoprotein 1, tazarotene induced 
gene-1, CTGF, downregulation of bone morphogenic protein 7, which is a known 
negative regulator of fibrosis have been reported.  TGF-β is implicated as one of the 
main triggers for increased collagen production and decreased matrix degradation 
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pathways in OSMF. Basic Fibroblast Growth Factor (Bfgf) is increased in fibroblasts 
and in endothelial cells in early disease and in advance fibrosis b-FGF expression was 
noted more in the stroma21. It was reported that the homologous wild genotype 
tumour necrosis factor (TNF)-α2 was significantly associated with an increased risk of 
OSMF through the modulation of collagen metabolism. With the available literature 
on growth factors and cytokines TGF-β appears to be the main mediator of the disease 
and others such as TNF-α, insulin-like growth factor-1, b-FGF and CTGF, may 
contribute to continuous accumulation of collagen with activation of signalling 
pathways such as ALK5, JNK, SMAD and p38 MAPK17. 
 
MALIGNANT TRANSFORMATION OF ORAL SUBMUCOUS FIBROSIS 
Malignant transformation of OSMF was first described in 1956. In a 17 year follow 
up study Murti et al., reported a malignant transformation of 7.6%. A study from 
Kolkata, India reported a malignant transformation rate of 2.6% whereas a report 
from Nagpur, India found a transformation rate of 3.3%.  A similar study from 
Taiwan found malignant transformation in epithelial dysplasia with OSMF to be 
4.84% whereas the transformation with OSMF alone was found to be 3.72%. The 
highest transformation rate was 7.6% from India, as reported in IARC monograph on 
OSMF7.Studies have reported a gender difference in the risk of malignant 
transformation of OSMF. Hazarey et al., reported an increased risk of malignant 
transformation of OSMF in men (male/female ratio= 5:1). Considering that most  
 
 
                                                                                                          Review of literature 
 
studies report a male gender predilection in the occurrence of OSMF22 and oral 
cancers, it stands to reason that the gender ratio of malignant transformation of OSMF 
should favour the male gender5. 
 
Areca nut as a carcinogen 
The major alkaloid of areca nut, arecoline, is well known for its different 
cytotoxic and genotoxic properties. The ultimate carcinogen in areca nut related oral 
carcinogenesis is arecoline N –oxide, the active metabolite of arecoline. Areca nut 
alkaloids inhibit cell growth and induce cell cycle exit in human oral fibroblasts 
Arecoline reduces p21 and p27 levels, thereby facilitating G1/S transition of the cell 
cycle and leads to error prone DNA replication22. Arecoline upregulates αVβ6 
expression and thereby promotes keratinocyte migration and induces invasion23. The 
cyclooxygenase 2 (COX 2) gene in fibroblasts is upregulated as a response to 
arecoline at early stage of OSMF, and it is more pronounced in OSCC compared with 
premalignant lesions24. 
The high copper content in areca nut influences tumour angiogenesis by activating 
several angiogenic factors such as VEGF, TNF-α, IL-1 A and basic fibroblast growth 
factor (b-FDF). These molecules stimulate endothelial cell proliferation and 
activation22. 
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The areca nut carcinogenicity can, in part, be attributed to exposure of oral 
mucosal cells to reactive oxygen species (ROS), methylating agents and reactive 
metabolic intermediates from areca nut and its constituents22. 
Hypoxia 
Hypoxia inducible factor 1α (HIF-1α), a known transcription factor induced 
by hypoxia is upregulated at both protein and mRNA levels. It is a key regulator of 
the cellular response to hypoxia and is associated with activation of many hypoxia–
inducible genes, such as genes encoding for VEGF22. Hypoxia and HIF-1α together 
play a role in malignant transformation of OSMF25. Increased fibrosis of connective 
tissue causes reduction of vascularity resulting in hypoxia and subsequent 
overexpression of HIF-1α22. 
Alterations in cell cycle 
The proliferating activity, as denoted by the proliferating cell nuclear antigen index, 
was higher in OSMF epithelium than normal mucosa. Increased proliferating cell 
nuclear antigen index may correlate with the increased malignant transformation 
potential. The important molecules in G2/M phase namely cyclin B1, p34, p-survivin 
play a key role in carcinogenesis by influencing mitosis. Their expression was found 
to be higher in OSMF than in normal mucosa and a significant difference was present 
in the expression between OSMF and OSCC. p63 in concert with p53 regulates cell 
proliferation and differentiation. The significant increase in expression of p53 and p63 
proteins in OSCC and OSMF suggest their role as surrogate markers of malignant 
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transformation26. Survivin inhibits apoptosis while promoting cell division. It is a 
protein expressed mainly in the G2/M phase, in a cell cycle –dependent manner and 
survivin Thr34 phosphorylation is the crucial requirement during the malignant 
transformation of OSMF both by inhibiting apoptosis and encouraging mitosis in 
carcinogenesis27. 
Alterations in Oncosuppressor genes and other genes 
A progressive reduction of PTEN expression, a known tumour suppressor 
gene was noticed as normal oral mucosa changes into OSMF and then into OSCC 
thus playing an important role in pathogenesis and carcinogenesis of OSMF. BRCA1 
and BRCA2 are tumour suppressor genes involved in the maintenance of genomic 
integrity by facilitating error free DNA repair. Chronic exposure to areca nut extract 
declines BRCA1 and BRCA2 proteins causing genomic instability. Arecoline 
increases the expression of hTRET in both mRNA and protein levels in oral 
keratinocytes and this overexpression plays an important role in malignant 
transformation of OSMF.  
Chronic OSMF is significantly associated with hypermethylation of E-
cadherin and COX -2, which is a mutation of the epigenetic level and hence more 
prone to malignant transformation22. 
Contribution of INTEGRIN αVβ6 in malignant transformation 
αVβ6 integrin is known for its ability to promote tissue fibrosis as well as 
carcinoma invasion,  and its expression is high in OSMF. Arecoline, the major  
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alkaloid of areca nut, upregulates αVβ6 expression in oral keratinocytes and induces 
their migration and invasion23. 
Senescence  
Areca nut alkaloids induce markers of cellular senescence in human oral 
fibroblasts and secrete molecules capable of promoting OSCC invasion and 
discohesion . 
The senescent fibroblasts produce a considerably higher amount of MMP-1 
and MMP-2 which may locally alleviate the fibrosis before their clearance by the 
innate immune system28. 
Epithelial mesenchymal transition (EMT) may be modulated by TGFβ1 and Ras. 
Senescence associated secretory phenotype (SASP) can promote malignant 
phenotypes and induces an epithelial –to - mesenchymal transition, a critical step in 
the development of invasive and metastatic carcinoma22.  
Description of histopathology of malignant transformation of OSMF stems from the 
1) The defining lesion of OSMF occurs in the connective tissue, whereas malignancy 
arises in the epithelium (OSCC) and the term “malignant transformation of OSMF” 
implies causal association between the occurrence of OSCC and OSMF. 
2) Demonstrable changes in the oral mucosa connective tissue may influence the    
malignant transformation, its progress and metastasis. 
3) Demonstrable changes in the epithelium and connective tissue appear to work in a 
co-ordinated fashion and therefore aptly the term epithelial mesenchymal transitions5. 
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Epithelial mesenchymal transition (EMT) may be modulated by TGFβ1 and Ras 
In OSMF, the oral epithelium demonstrates impairement in progressive maturation 
and simultaneous increase in basement membrane thickness and subepithelial 
collagen deposition along with the alterations in target molecular expressions. 
Compared with the nondysplastic conditions, dysplastic stages exhibited significant 
increase in expressions of epithelial master regulator p63 along with loss of E-
cadherin and its associate β catenin and gain of mesenchymal markers such as N-
cadherin and TWIST which are also indicators of EMT in OSMF30. 
An immunohistochemical study by Ranganathan K et al., (2006) was carried 
out to characterize the cytokeratin (CK) profile in OSMF. Archived tissue blocks of 
OSMF (n = 50), normal (n = 10) and OC (n = 10) were stained with pancytokeratin 
(PanCK), high molecular weight cytokeratin (HMWCK), Cytokeratins 18, 14, 8, 5, 4 
and 1. Significant difference in the CK staining pattern was seen between normal, 
OSF and cancer. Significant changes in OSMF included increase in the intensity of 
staining for pancytokeratin and HMWCK, aberrant expression of CK8 and decreased 
expression of CK 5 and CK14, suggesting their potential as surrogate markers of 
malignant transformation31.  
Another study by Nanda KD et al.,(2012) showed increased expression of 
CK8 and CK18 in dysplasia, OSMF and OSCC. The staining pattern and intensity 
showed variations, with staining intensity in the basal and suprabasal layers for CK8 
and CK18 suggesting them as surrogate markers of malignant transformation32. 
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Thus, with the effect of epithelial mesenchymal transition, in OSMF, keratinocytes in 
the epithelium could be altered in such a manner that the altered keratin profiles 
would influence the disease pathogenesis as well as the predisposition to malignant 
transformation33. 
Genetic susceptibility 
Genomic instability in the form of loss of heterozygosity (LOH) is present in 
OSMF. Since the chromosome 13q is highly susceptible to genomic instability in 
head and neck squamous cell carcinoma34. 
Angiogenesis- related molecules 
Decreased vascularity in the underlying connective tissue stroma is 
responsible for the ischemic atrophy of the epithelium in OSMF. Endogenous 
angiogenic promoters such as inducible nitric oxide synthase (iNOS), b-FGF, 
Transforming growth factor (TGF)-β, Platelet derived growth factor (PDGF) and HIF-
1α are found to be expressed in OSMF and play an important in maintaining the 
vascularity of underlying connective tissue35. 
Increase in vasculature is an adaptive response of the mucosa, to cope with the 
hypoxia created by progressive fibrosis. This angiogenesis plays an important role in 
tumour proliferation, once the malignant transformation takes place36. A study done 
by Anura et al., evaluated prospective molecular pathology markers for OSMF 
progression using a computer aided quantitative assessment framework  proposed that  
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VEGF may be used for risk stratification and VEGF receptor (VEGFR) II and 
CD 105 for prognosis of OSMF into oral cancer37. 
Arecoline, the principal alkaloid in areca nut, has been proven to be cytotoxic for 
epithelium and the fibroblasts via cell necrosis. The vascularity of the mucosa is 
known to reduce with advanced fibrosis and starts to increase in the juxtaepithelial 
area once dysplasia appears in the epithelium. Recent study of morphologic analysis 
of mucosal vasculature in OSMF showed that vascularity was increased in early 
OSMF and reduced in advanced OSMF, with the suggestion that inflammation may 
play a role in the early stages, whereas progressive fibrosis may predispose to atrophy 
of the epithelium and subsequent malignant changes22. CD34, a member of 
sialomucin protein family plays an important role in cell to cell adhesion. Desai et al., 
assessed immunohistochemical expression of CD34 in malignant transformation of 
atrophic epithelium in oral submucous fibrosis which demonstrated increase in mean 
vascular luminal diameter and mean vascular area percentage in OSMF compared to 
normal tissue36.  
Pandiar et al., evaluated the immunoreactivity of CD34 and b-FDF in 
different histological grades of OSMF support the same concept that vascularity 
increased significantly in cases of OSMF turning towards malignancy38. In a similar 
study by using toluidine blue immunohistochemical analysis of angiogenesis by CD34 
and mast cells in different grades of OSCC also showed that the mean expression of 
CD34 was higher in different grades of OSCC as compared to normal mucosa8. 
 
 
Review of literature 
 
Rajendra et al., proposed another explanation to address the varied findings 
of blood vessel sizes in OSMF. They suggested that as the connective tissue gets 
denser, physical and biochemical restriction to blood vessel growth results, and this 
indicates angiogenic activity. It is important to assess this theory because of its 
implications related to the potential for targeting angiogenesis to prevent the 
malignant transformation of OSMF39. 
There is strong linkage between angiogenesis and mast cells, since mast cells have 
been demonstrated to accumulate in many angiogenesis dependent situations, 
including tumour growth, through variety of factors such as stem cell factor, VEGF, 
EDGF, Bfgf, PDGF and induce chemotactic migration of mast cells to sites of 
neovascularisation. Tryptase, a proteolytic enzyme, is produced by mast cells, which 
degrade the connective tissue matrix40. 
In a study by Anak et al; (2002) mast cell density was significantly higher in 
pre-malignant dysplasia than hyperkeratosis and normal mucosa suggesting that mast 
cells may upregulate angiogenesis in premalignant as well as squamous cell 
carcinoma by the release of tryptase4. 
VEGF does not stimulate the growth of tumour cells directly but leads to the 
growth and increase of permeability of endothelial cells. VEGF induces 
neovascularisation and promotes extravasation of plasma fibrinogen, leading to 
alteration of tumour extracellular matrix and promoting metastasis by breaking down 
the ECM in tumour microenvironment4.                                  
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Oral Squamous Cell Carcinoma 
Introduction- 
Oral carcinogenesis is a sequential and multi‑ step process which is carried out by the 
deregulation of crucial molecular pathways, among which angiogenesis has long been 
considered one of the most important mechanisms involved in the biology of cancer.  
Numerous tumours promote growth and dispersion to form metastases by recruiting 
host blood vessels to grow into the vicinity of the tumour. Angiogenic switch is 
determined by the net balance of natural inhibitors and angiogenic stimulators, out of 
which vascular endothelial growth factor (VEGF), also termed VEGF-A, is 
considered to be the major stimulator responsible for tumour angiogenesis6. 
 
Cancer’s Angiogenic switch 
Tumour cells may overexpress one or more of the positive regulators of 
angiogenesis, may mobilize an angiogenic protein from the ECM, may recruit host 
cells such as macrophages (which produce their own angiogenic proteins), or may 
engage in a combination of these processes. Tumour angiogenesis is mediated by 
tumour-secreted angiogenic growth factors that interact with their surface receptors 
expressed on ECs. The most commonly found angiogenic growth factors such as 
VEGF and bFGF, when encounter ECs, they bind to the tyrosine kinase receptors on 
ECs membrane. Binding leads to dimerization of the receptors and activation of 
autophosphorylation of tyrosines on the receptor surface and thereby initiates the  
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several signaling proteins (including PI3kinase, Src, Grb2/m-SOS-1 (a nucleotide 
exchange factor for Ras) and signal transducers and activators of transcriptions 
(STATs) each of which contains src-homology-2 (SH-2) domains. Binding of the SH-
2 regions of these proteins to the phosphotyrosines on the receptor tyrosine kinases 
(RTKs) activates several pathways that are crucial for triggering the cell cycle 
machinery. The most well studied pathway passes through the GTP-binding protein 
Ras and activates the mitogen activated protein kinase (MAPK) cascade and 
subsequently transcription factors in the nucleus. Up-regulation of an angiogenic 
factor is not sufficient in itself for a tumour cell to become angiogenic, however, 
certain negative regulators or inhibitors of vessel growth may need to be down-
regulated12. 
Prognostic value of VEGF-A in Oral Squamous Cell Carcinoma (OSCC): 
Tumour angiogenesis and lymphangiogenesis play an essential role in the 
growth, invasion, and metastatic spread of solid neoplasms. Expression of VEGF-A 
was found to be related to tumour progression or poor prognosis in several human 
malignancies, including breast cancer, lung cancer, gastric cancer, pancreatic cancer 
and prostate cancer. Overexpression of VEGF-A has been reported to be signiﬁcantly 
associated with lymph node metastasis, histological differentiation, recurrence and 
poor prognosis in head and neck cancer41. 
VEGF expression was reported to correlate with clinical parameters including 
tumour size, lymph node metastasis and prognosis42. The process of metastasis may  
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take place in two stages: prevascular and vascular. In the prevascular stage, 
marginal tumour cells locally invade host stroma surrounding the primary tumour 
without vascular invasion, which is associated with limited growth. In the vascular 
phase, tumour cells enter blood vessels or lymphatic vessels, which is associated with 
rapid growth or metastasis. Although neovascularization is necessary to become the 
vascular phase, it is controlled by the balance of positive and negative regulators. 
VEGF does not stimulate the growth of tumour cells directly, but leads to the growth 
and increase of permeability of endothelial cells. VEGF serves to induce 
neovascularization around tumour cells and promotes extravasation of plasma 
fibrinogen, leading to the alteration of the tumour extracellular matrix and promoting 
metastasis by breaking down the extracellular matrix in the tumour 
microenvironment. These may be an important role of VEGF on tumour cells42. 
Mineta et al., (2000) found that VEGF expression was associated with lymph 
node status in head and neck squamous cell carcinoma42. 
In a study by Carlile et al.,(2001) possible involvement of VEGF in field 
cancerisation was done using two different antibodies of VEGF(goat polyclonal 
antibody raised against human rhVEGF165  and the other rabbit polyclonal antibody 
raised against aminoacids 1-20 of VEGF165 )which showed that VEGF indices in the 
epithelium were similar in normal oral mucosa, dysplasia and  carcinoma. Vascularity 
values increased from normal oral mucosa to dysplasia and from dysplasia to 
carcinoma (OSCC) 7. 
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Baillie et al., (2001) compared the expression of VEGF by using five different 
antibodies in normal and oral tissues and had conflicting results due to the presence of 
different ratios of VEGF isoforms in various tissues43. 
Gallo et al., (2001) showed that Cyclooxygenase 2(COX-2) was 
overexpressed in head and neck carcinoma tissues when compared to adjacent normal 
tissue. Increase in COX-2 mRNA and protein expression is associated with an 
increase in PgE2  production from tumour tissue, particularly at the tumour edge, and 
is significantly correlated with the occurrence of lymph node metastasis in head and 
neck carcinoma patients44. 
Shang et al., (2002) analysed the levels of VEGF in oral squamous cell 
carcinoma and determined their correlation with the clinicopathologic features and 
prognosis. Serum VEGF was found to be increased in patients with OSCC and higher 
serum VEGF was associated with lymph node metastasis and clinical staging in 
OSCC patients45. 
Shang et al., (2005) determined the expression of endothelial nitric oxide 
synthase (eNOS) and VEGF in oral squamous cell carcinoma. Nitric oxide (NO) is 
thought to play an important role in assisting tumour growth, facilitating 
dissemination and 
actively promoting angiogenesis. eNOS is mainly localised in the endothelium. NO 
produced by eNOS is a signalling molecule in blood vessels, where a continuous  
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formation from endothelial cells acts on underlying smooth muscle to maintain 
vasodilation and nutritious blood flow. In this study it was found that 
neovascularisation is most pronounced in eNOS and VEGF positive tumours 
suggested that an enhanced vascularity reflects an increased risk of metastasis46. 
Shintani et al., (2005) evaluated microvessel density and expression of 
VEGF, bFDF and PDGF which was significantly upregulated in OSCC. VEGF 
expression correlated with Mean Vascular Density (MVD), tumour differentiation and 
stage of invasion47. 
Shang et al., (2006) et al studied that VEGF was upregulated by hypoxic 
stimulation and was found to be related to tumour angiogenesis and severity of 
disease in OSCC patients48. 
Johnstone et al., (2007) suggested a significant upregulation of VEGF 
expression during transition from normal oral mucosa, through dysplasia to OSCC. 
Among the dysplastic lesions examined in this study, he found that there was no 
correlation between VEGF expression and grade of dysplasia suggesting that any 
increase in dysplasia is not necessarily accompanied by an increase in VEGF 
expression49. 
Shang et al., (2007) compared the serum levels of VEGF with VEGF 
positivity through immunohistochemistry and found that they both were closely  
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associated with both regional lymph node status and clinical stage of patients with 
OSCC50. 
Shao et al., (2008) concluded that protein level of VEGF was significantly 
higher in tongue cancer than in normal mucosa and it positively correlated to MVD. 
EphA2, 
VEGF, MVD and TNM stage were associated with a shorter survival period and were 
determined to play an important role in the prognosis of tongue cancer51. 
Claudiu et al., (2010) demonstrated that VEGF was expressed in 87% of 
OSCC tumour specimens when compared to pre neoplastic and normal tissues. VEGF 
expression was reduced in poorly differentiated OSCC tumours when compared to 
moderate and well differentiated forms. They did not demonstrate any correlation 
between VEGF expression, tumour microvascular area, clinical stage and lymph node 
status52. 
Seema Nayak et al., (2011) demonstrated that VEGF expression was 
significantly higher in OSCC with lymph node involvement than those without lymph 
node. 
No significant association was found with clinical stage of tumour and degree 
of differentiation in OSCC. In this study, VEGF-A levels in serum correlated  with the 
tissue expression in both oral premalignant and malignant lesions. Thus, serum levels 
of VEGF can be used as a surrogate marker for tissue expression of VEGF-A12. 
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Gandolfo et al., (2011) found out in his study that subepithelial 
vascularisation and VEGF expression increase in leukoplakia and even more in cases 
with dysplasia reveals that both these histochemical reactions can be used as 
diagnostic aid in the evaluation of severity of potentially malignant lesions53. 
Seki et al., (2011) analysed factors to improve prognostic prediction of OSCC 
using vasculogenesis associated markers. He suggested that strong positive expression 
of either VEGF-A or VEGF-C was an effective predictor of OSCC not only in 
advanced stages but also in early stages54. 
Naruse et al., (2011) in his study indicated that mTOR –HIFα-VEGF pathway 
affects the progression of OSCC and inhibition of this pathway may be useful for the 
treatment of OSCC. He also suggested that VEGF-A may correlate with the tumour 
growth while VEGF-C correlates with invasion13. 
Madhusudan et al., (2012) indicated that VEGF and Mean Vascular Density 
(MVD) appeared to increase with disease progression and were statistically higher in 
OSCC than in epithelial dysplasia and normal mucosa55. 
Ravi et al., (2012) evaluated the ability of VEGF expression in identifying 
tumour-related alterations in histologically related surgical margins. He also studied 
the expression of VEGF in HNSCC and the peripheral normal tissue and correlated 
their expression with the metastatic potential of the tumours56. 
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Nakisa et al., (2014) proved that though the expression of VEGF was 
significantly higher in OSCC group as compared to the dysplastic or normal 
group,there was no difference in the VEGF expression between the dysplastic mucosa 
and normal mucosa57. 
Noushin et al., (2015) showed in his study that VEGF expression correlates 
with tumour size but no correlation was seen between VEGF expression with lymph 
node involvement, tumour differentiation, gender and age. There was negative 
association between VEGF expression and histological grade and lymph node 
metastasis58. 
Kim et al., (2015) demonstrated that VEGF gene expression was increased in 
OSCC than in normal tissues or intraepithelial carcinoma and the correlation between 
VEGF expression and degree of histological differentiation of OSCC59. 
Martano et al., (2016) concluded that VEGF expression was strongly 
correlated with proliferating cell nuclear antigen (PCNA) marker and microvessel 
diameter. VEGF promotes angiogenesis through a paracrine pathway stimulating 
endothelial cell proliferation and induces tumour cell proliferation via an autocrine 
pathway6. 
Caroline et al., (2016) observed that angiogenesis is a key factor not only for 
tumour development but also for tumour progression and metastasis. The higher 
VEGF-A transcript levels detected in tumour margin samples support the field  
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cancerisation suggesting that cells adjacent to the tumour are actively involved in the 
production of tumour growth factors60. 
Madhavannirmal et al., (2016) demonstrated that a significant increase in 
Mean Vascular Density was observed between OSMF with no epithelial changes and 
OSMF with epithelial dysplasia and concluded that epithelial secreted VEGF played a 
pivotal role in either sustaining or stimulating angiogenesis that support tumour 
growth and invasion in OSF patients61. 
The VEGF plays a decisive role in the development of blood vessels; it is a key 
component in tumour angiogenesis and 4 subtypes (A, B, C, D) have been described.  
 Shintani et al., recently described its expression in OSCC, correlating 
subtypes A and B with tumour angiogenesis and subtypes C and D with the risk of 
nodal metastasis.The latter were frequently upregulated in the invasive front of 
tumour indicating a possible role in the process of tumour invasion and development 
of metastasis62. 
Uehara et al., found a significant correlation between high expression of 
VEGF in OSCC and worse prognosis62. 
Bhavana Gupta et al., (2016) reviewed and highlightened the role of VEGF 
in health and various oral diseases9.VEGFR-1 regulates blood vessel morphogenesis 
as this receptor is required for normal blood vessel development during 
embryogenesis. VEGFR-2 regulates vessel permeability by loosening the junctions  
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between endothelial cells giving rise to formation of transcellular gaps. VEGFR-3 
regulates lymphangiogenesis9. 
 
VEGF expression in oral lesions 
1) In potentially malignant lesions and in OSCC- 
The potential biomarkers for carcinogenesis such as VEGF, MMP2 and 
MMP9 were analysed by Mukherjee et al., in OSMF and leukoplakia as well 
as OSCC I comparison to normal. 
2) In salivary gland tumours 
Faur et al., studied 45 cases of salivary gland lesions and concluded that 
VEGF expression is significantly more important in malignant salivary 
tumours as compared with benign ones9. 
3) In inflammatory and reactive lesions 
VEGF expression was detected in healthy gingival, periodontitis and pyogenic 
granuloma by Yuan et al. Expression of VEGF was found to be strongly 
positive in the inflammatory infiltrate in irreversible pulpitis63. 
4) In odontogenic cysts and tumours 
Rubini et al., established a significant different expression of VEGF in 
keratocysts compared with follicular cysts which showed more than 50% 
VEGF positive epithelial cells. Nouaem et al., concluded that VEGF acts as 
an important factor of angiogenesis in epithelial odontogenic tumours. 
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5) In other lesions 
            Amura et al., established that VEGF can promote cholangiocyte proliferation  
            and Sato et al., studied VEGF in cyst fluid of enlarging and recurrent thyroid  
            nodules. 
6) In vascular diseases 
Hemangioma, Lymphangioma and Kaposi’s sarcoma showed strong 
expression of VEGF9. 
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Results 
  
SAMPLE CHARACTERISTICS: 
The study population includes 40 cases taken from the archival blocks. They 
were categorized into four groups. Group I (n=10) comprised of normal mucosa 
samples. Group II (n= 10) comprised of Oral Submucous Fibrosis samples. Group III 
(n=20) comprised of Oral Squamous Cell Carcinoma samples. All the samples were 
analyzed for the immunoreactivity of VEGF stain. 
 
DISTRIBUTION OF AGE IN THE STUDY GROUPS:  
(TABLE 1 & GRAPH 1):  
The distribution of age of the patients was divided into 3 groups as 21-40 
years, 41-60 years and those above 60 years of age. Group I was entirely in the age 
group 21-40 years. Group II consisted of 1 (10%) cases in 21-40 years, 8 (80%) cases 
in 41-60 years and 1 (10%) cases above 60 years. Group III consisted of 4 (20%) 
cases in 21-40 years, 7 (35%) cases in 41-60 years and 9 (45%) cases of above 60 
years. The difference was statistically significant(p=0.000)   
 
DISTRIBUTION OF GENDER IN THE STUDY GROUPS  
(TABLE 2 & GRAPH2):  
In Group I, 2 (20%) were males and there were 8 (80%) females. In Group II, 
8 (80%) were males and there were 2 (20%) females. In Group III, 14 (70%) were 
males and 6 (30%) were females. The distribution was statistically 
significant(p=0.010) 
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DISTRIBUTION OF HABITS IN THE STUDY GROUPS:  
(TABLE 3 & GRAPH 3):  
Based on the prevalence of habits in the study groups, they were categorized 
into five groups. They were those without any habits(n=20), those with habit of 
chewing tobacco alone(n=15), chewing tobacco and consuming alcoholic 
beverages(n=2),  smoking & consuming alcoholic beverages(n=2) and chewing 
tobacco & smoking(n=1). In Group I (control group) none of them had any habits. In 
Group II, there were 7 (70%) with habit of chewing tobacco alone, 1 (10%) had the 
habit of chewing tobacco and consuming alcohol, 1 (10%) had the habit of smoking 
and consuming alcohol and 1 (10%) had the habit of chewing tobacco and smoking. 
In Group III, 10 (50%) of the cases had no habit, 8 (40%) had the habit of chewing 
tobacco alone, 1 (5%) had the habit of chewing tobacco and consuming alcohol and 1 
(5%) had the habit of chewing tobacco and smoking. The distribution of habits among 
the 3 groups was statistically significant(p=0.006). 
 
DISTRIBUTION OF SITE IN THE STUDY GROUPS (TABLE 4 & GRAPH 4):  
In Group I, all incisional biopsies were from retro-molar region while in 
Group II, all were from buccal mucosa. In Group III, 7 (35%) were from lateral 
border of tongue and 6 (30%) were from buccal mucosa, 1 (5%) was from palatal 
region and 1 (5%) case was from alveolar mucosa, 4 (20%) were from gingiva and 1 
(5%) was from vestibule. The distribution of site among 3 groups was found to be 
statistically significant(p=0.000). 
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DISTRIBUTION OF STAINING OF VEGF IN THE STUDY GROUPS 
(TABLE 5 & GRAPH 5):  
Of the total number of cases subjected to VEGF staining, in Group I, 7 (70%) 
showed positivity while 3 (30%) were negative. In Group II, all cases showed 
positivity. In Group III, all 20 cases showed 100% positivity(p=0.008).  
Brown colour of VEGF staining was seen as cytoplasmic or membranous localisation. 
VEGF Expression was assessed by scoring the intensity of staining and the area of  
staining.  
Staining intensity was scored as follows: 0=no staining, 1=mild staining, 
2=moderate staining, 3=intense staining. 
The area of staining was scored as: 0=no staining, 1=<25% of cells stained positively,  
2=25%-50% of cells stained positively, 3=>50% of cells stained positively. 
TISSUE EXPRESSION OF THE STAIN (TABLE 6 AND GRAPH 6): 
  In Group I, 7 (70%) cases showed >50% positivity and 3 (30%) cases did not 
take up the stain. In Group II, 1(10%) case showed 25-50% positivity and 9 (90%) 
cases showed >50% positivity. Positive immunolocalisation was seen in the basal and 
suprabasal layers in Group II (OSMF).  In Group III, 1(5%) case showed 25-50% 
positivity and 19 (95%) cases showed >50 % positivity(p=0.033). In Group III 
(OSCC), positive cytoplasmic VEGF staining was seen in tumour nest cells. 
Periphery cells of cancer nests were more heavily stained than the central cells of 
cancer nests. Stromal staining was excluded for recording of positive expression. 
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STAINING INTENSITY  
COMPARISON OF VEGF INTENSITY BETWEEN THE STUDY GROUPS 
(TABLE 7 & GRAPH 7):  
On comparing the VEGF intensity between the study groups, Group I showed 
3(30%) and 7 (70%) of negative and mild staining respectively. Group II showed 8 
(80%) and 2 (20%) of mild and moderate staining respectively. In Group III 14 (70%) 
and 6 (30%) cases showed mild and moderate staining respectively. There was no 
intense staining in any of the groups(p=0.017). 
 
COMPARISON OF VEGF INTENSITY BETWEEN GROUPS I  
AND GROUP II (TABLE 8 & GRAPH 8):  
Group I showed 3 (30%) cases negative and 7 (70%) cases with mild intensity 
of staining. Group II showed 8 (80%) cases mild and 2 (20%) cases with moderate 
intensity of staining. The distribution of VEGF intensity between Groups I and II was 
statistically not significant(p=0.079). 
COMPARISON OF VEGF INTENSITY BETWEEN GROUPS I AND  
GROUP III (TABLE 9 & GRAPH 9):  
Group I showed 3 (30%) cases negative and 7 (70%) cases with mild intensity 
of staining. Group III showed 14 (70%) cases mild and 6 (30%) cases with moderate 
of intensity. The distribution of VEGF intensity between Group I and Group III was 
found to be statistically significant(p=0.011). 
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COMPARISON OF VEGF INTENSITY BETWEEN GROUPS II AND  
GROUP III (TABLE 10 & GRAPH 10):  
Group II showed 8 (80%) cases mild and 2 (20%) cases with moderate 
intensity of staining. Group III showed 14 (70%) cases mild and 6 (30%) cases with 
moderate of intensity(p=0.452). 
COMPARISON OF VEGF INTENSITY BETWEEN THE GRADES OF OSCC 
(TABLE 11& GRAPH 11):  
The grades of OSCC were divided into well differentiated (n=17) and 
moderately differentiated (n=3). In well differentiated OSCC, 11 (64.7%) cases 
showed mild intensity and 6 (35.3%) cases showed moderate intensity of staining. In 
moderately differentiated OSCC, all 3 (100 %) cases showed mild intensity of 
staining. This was found to be statistically not significant(p=0.319). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
* p value < 0.05 is significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE GROUP 
(IN YEARS) 
GROUP 1 
(n=10) 
GROUP 2 
(n=10) 
GROUP 3 
(n=20) 
p value 
21-40 10 (100%) 1 (10%) 4 (20%) 0.000* 
41-60 0 8 (80%) 7 (35%) 
>60 0 1 (10%) 9 (45%) 
TABLE 1: DISTRIBUTION OF AGE IN STUDY GROUPS (N=40) 
GRAPH 1: DISTRIBUTION OF AGE IN STUDY GROUPS (N=40) 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
  
 
 
 
 
 
 
 
 
 
 
 
* p value < 0.05 is significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENDER GROUP 
1(n=10) 
GROUP 2 (n= 
10) 
GROUP 
3(n=20) 
p value 
MALE 2 (20%) 8 (80%) 14 (70%) 0.010* 
FEMALE 8 (80%) 2 (20%) 6   (30%) 
TABLE 2: DISTRIBUTION OF GENDER IN STUDY GROUPS (N=40) 
GRAPH 2: DISTRIBUTION OF GENDER IN STUDY GROUPS (N=40) 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
  
 
 
 
 
 
 
 
* p value < 0.05 is significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HABITS GROUP 1(n=10) GROUP 2(n=10) GROUP 3(n=20) p value 
 
0.006* 
No habits 10(100%) 0 10 (50%) 
Chewing alone 0 7 (70%) 8 (40%) 
Chewing+ 
alcohol 
0 1(10%) 1(5%) 
Smoking + 
alcohol 
0 1 (10%) 1(5%) 
Chewing+ 
smoking 
0 1 (10%) 0 
GRAPH 3: DISTRIBUTION OF HABITS IN STUDY GROUPS (N=40) 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
TABLE 3: DISTRIBUTION OF HABITS IN STUDY GROUPS (N=40) 
  
 
 
 
 
SITE OF 
LESION 
GROUP 1 
   (n=10) 
GROUP 2 
  (n=10) 
GROUP 3 
  (n=20) 
p value 
Retromolar 
region  
10(100%) 0 0 0.000* 
Lateral border 
of tongue 
0 0 7(35%) 
Buccal mucosa 0 10(100%) 6(30%) 
Palate 0 0 1(5%) 
Alveolar mucosa 0 0 1(5%) 
Gingiva 0 0 4(20%) 
Vestibule 0 0 1(5%) 
 
*p value < 0.05 is significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 4: DISTRIBUTION OF SITE OF LESION/BIOPSY AMONG STUDY GROUPS (N=40) 
GRAPH 4: DISTRIBUTION OF SITE OF LESION/BIOPSY AMONG STUDY GROUPS (N=40) 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
  
 
 
 
 
 
 
 
VEGF staining GROUP 1 
   (n=10) 
GROUP 2 
   (n=10) 
GROUP 3 
   (n=20) 
p value 
PRESENT 7(70%) 10(100%) 20(100%) 0.008* 
ABSENT  3(30%) 0 0 
 
*p value < 0.05 is significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 5: DISTRIBUTION OF STAINING OF VEGF AMONG STUDY GROUPS (N=40) 
GRAPH 5: DISTRIBUTION OF STAINING OF VEGF AMONG STUDY GROUPS (N=40) 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
  
 
 
 
 
TISSUE 
EXPRESSION 
GROUP 1 
(n=10) 
GROUP 2 
(n=10) 
GROUP 3 
(n=20) 
p value 
NEGATIVE 3(30%) 0 0 0.033* 
<25% 0 0 0 
25-50% 0 1(10%) 1(5%) 
>50% 7(70%) 9(90%) 19(95%) 
 
 
*p value < 0.05 is significant 
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TABLE 6: EXPRESSION OF VEGF IN TISSUES IN THE STUDY GROUPS (N=40) 
GRAPH 6: EXPRESSION OF VEGF IN TISSUES IN THE STUDY GROUPS (N=40) 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
  
 
 
 
 
 
VEGF staining 
intensity 
GROUP 1 
   (n=10) 
GROUP 2 
   (n=10) 
GROUP 3 
   (n=20) 
p value 
Negative 3(30%) 0 0 0.017* 
Mild 7(70%) 8(80%) 14(70%) 
Moderate 0 2(20%) 6  (30%) 
Intense 0 0 0 
 
 
 
*p value < 0.05 is significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 7: COMPARISON OF VEGF INTENSITY BETWEEN THE STUDY GROUPS (N=40)  
  
 
GRAPH 7: COMPARISON OF VEGF INTENSITY BETWEEN THE STUDY GROUPS (N=40)  
  
 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
  
 
 
 
 
 
 
VEGF  
INTENSITY  
GROUP 1(n=10) GROUP 2 (n=10) p value  
 
0.079 Negative 3 (30%) 0  
Mild 7 (70%) 8 (80%) 
Moderate 0 2 (20%) 
Intense 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 8: COMPARISON OF VEGF INTENSITY BETWEEN GROUP 1 AND GROUP 2 (N=40)  
  
 
GRAPH 8: COMPARISON OF VEGF INTENSITY BETWEEN GROUP 1 AND GROUP 2 (N=40) 
  
 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
 
   
 
 
 
 
 
 
VEGF  
INTENSITY  
GROUP 1(n=10) GROUP 3 ( n=20) p value 
 
0.011* Negative 3 (30%) 0  
Mild 7 (70%) 14 (70%) 
Moderate 0 6 (30%) 
Intense 0 0 
 
*p value < 0.05 is significant 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 9: COMPARISON OF VEGF INTENSITY BETWEEN GROUP 1 AND GROUP 3 (N=40) 
  
 
GRAPH 9: COMPARISON OF VEGF INTENSITY BETWEEN GROUP 1 AND GROUP 3 (N=40) 
  
 
GROUP 1- NORMAL MUCOSA 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
 
  
 
 
 
 
 
 
VEGF  
INTENSITY  
GROUP 2 (n=10) GROUP 3 ( 
n=10) 
p value 
 
0.452 Negative 0  0  
Mild 8 (80%) 14 (70%) 
Moderate 2 (20%) 6  (30%) 
Intense 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA 
 
GRAPH 10: COMPARISON OF VEGF INTENSITY BETWEEN GROUP 2 AND GROUP 3 (N=40) 
  
 
TABLE 10: COMPARISON OF VEGF INTENSITY BETWEEN GROUP 2 AND GROUP 3 (N=40) 
  
 
  
 
 
 
 
 
VEGF  
INTENSITY  
WELL 
DIFFERENTIATED 
OSCC (n=17) 
MODERATELY 
DIFFERENTIATED 
OSCC (n=3) 
p value 
 
 
 
0.319 
Negative 0  0  
Mild 11 (64.7%) 3 (100%) 
Moderate 6 (35.3%) 0 
Intense 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 11: COMPARISON OF VEGF INTENSITY BETWEEN GRADES OF OSCC (N=40) 
  
 
GRAPH 11: COMPARISON OF VEGF INTENSITY BETWEEN GRADES OF OSCC (N=40) 
  
 
GROUP 1- NORMAL MUCOSA 
GROUP 2- ORAL SUBMUCOUS FIBROSIS (OSMF) 
GROUP 3- ORAL SQUAMOUS CELL CARCINOMA (OSCC) 
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 Discussion 
  
Oral Squamous Cell Carcinoma (OSCC) is the eleventh most common cancer 
worldwide64. It is one of the most common cancers in India which are likely to go up 
from 979,786 cases in the year 2010 to 1,148,757 cases in the year 202065. OSCC 
occurs as a result of multiple complex molecular events which develop from the 
combined effects of individual genetic predisposition, mutations and exposure to 
environmental carcinogens66. 
Angiogenesis and ECM degradation are two of several hallmarks of 
carcinogenesis, tumour development and metastasis. Vascular Endothelial Growth 
Factor (VEGF) is considered as one of the major contributing factor in angiogenesis67. 
Apart from playing a central role in regulating angiogenesis, it is also found to be 
tightly associated with angiogenic switch which is crucial in the progression of oral 
potentially malignant lesions to OSCC12. 
VEGF is a selective mitogen for vascular endothelial cells and may directly stimulate 
the development of new blood vessels. Elevation of VEGF also causes extravasation 
of plasma proteins (eg: fibrinogen) into extravascular space through increasing 
microvascular permeability. Then, extravasated fibrinogen clots and other proteins 
like fibronectin may get incorporated into a fibrin clot which is essential for 
endothelial cell growth48.  
Tumor angiogenesis is not essentially a feature of invasive tumour but may be 
an early event during tumorigenesis. Evidences of angiogenesis came from pre 
malignant squamous lesions such as in the oral mucosa and skin in which the 
angiogenic switch was established by the immunohistochemical expression of  
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VEGF68. The tumour angiogenesis and the expression of VEGF has been documented 
to be important prognostic factor in various malignancies and Potentially Malignant 
Disorders (PMD) which have a direct effect on tumour progression, local invasion of 
the tumour and lymph node metastasis. Unlike other PMDs, OSMF is unique in which 
there is excessive production and irreversible crosslinking of collagen, leading to 
progressive hyalinization of lamina propria and reduction in vascularity and cellular 
components, making it less conducive to support angiogenesis. The mechanism of 
tumour induced angiogenesis and the role of VEGF in such hostile micro-
environment to support tumour growth until now remains unclear61. 
Given the fact that VEGF has a vital role in the progression of tumorigenesis, 
this study was done on Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma 
using immunohistochemistry to study the expression of VEGF and was compared 
with that of the normal mucosa. 
Archival blocks were taken from the department for study purpose. The study 
population includes 40 cases. They were categorized into three groups. Group I 
(n=10) comprised of clinically normal mucosa samples which was obtained from 
retromolar region from the patients who came for the removal of impacted teeth.  
Group II (n= 10) comprised of OSMF tissue samples. Group III (n=20) comprised of 
OSCC tissue samples.  
In our study 80 % of the cases in group II (OSMF), 35% of cases in group III 
(OSCC) were in the age group between 40-60 years. The distribution of age of 
patients with OSMF and OSCC was statistically significant. Our data also suggests 
that 10% of cases in group II and 45% of cases in group III were seen above 60 years.  
Discussion 
  
This was consistent with the study of Pires FR et al., who stated that 46% of 
the patients were between 41 – 60 years and 41% of affected age group was between 
61 – 80 years in their study69.  
This study showed that males were predominantly affected than females 
among the study groups. The male and female ratio in the study group was found to 
be 2.5:1. 
ChenYJ et al., in his study of 703 OSCC cases, stated that 93% of their study 
population were males61. They also suggested that the prevalence of OSCC and 
OSMF was more common in males when compared to females. These findings were 
consistent with Chaturvedi et al., who stated the incidence of chewing habit is higher 
among Indian males compared to females especially in the lower socio economic 
category of population70.  
In our study, all OSMF  (group II) patients and 50 % of OSCC (group III) 
patients had the habit of chewing tobacco and consuming alcohol when compared to 
the control groups and this difference was statistically significant (p=0.006). This 
finding is consistent with the study of Ko YC et al., in which they substantiated that 
the combined used of substances such as betel nut, alcohol and tobacco increases the 
risk of oral cancer by 123 fold80. 
About 70% of group II patients and 40% of group III patients had the habit of 
chewing alone presented with Oral Submucous Fibrosis and Oral Squamous Cell 
Carcinoma. This was consistent with the study by Chourasia et al., in which 96.6 % 
of the patients having OSMF had the habit of betel nut chewing in different forms71.  
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Paymaster JC et al., in his study proposed that an increased frequency of cancer in 
the oral cavity was often associated with the habit of the chewing of tobacco with 
betel leaf, betel nut, and slaked lime than with other habits72 which was also 
consistent with this study.  
In our study 50% of OSCC cases did not have any habits and this finding was 
concurrent with the study of Shan Ho P et al., who in their prospective study of 148 
cases with OSCC, found that 40% did not have any habits73. 
In our study, buccal mucosa was the common site of biopsy in all cases of 
OSMF and in 30% cases of OSCC. This finding is consistent with the study of 
Chourasia et al., in which buccal mucosa was the most common site of occurrence of 
OSMF and OSCC71. In OSCC 35% cases were from the lateral border of tongue. This 
was concurrent with the study of Pires FR et al., who reported that the most common 
site of OSCC was the lateral border of tongue69. This finding was also consistent with 
Chen YJ et al., in whose study nearly 35% of OSCC occurred on the lateral border of 
tongue64.  
TISSUE EXPRESSION OF VEGF STAINING:  
In this study 70% of normal mucosa, all cases of OSMF and all cases of 
OSCC expressed VEGF staining. These findings are supported by those of Johnstone 
and Logan et al., who observed an epithelial positivity of VEGF-A in 40% of normal 
tissues, suggesting significant upregulation from normal mucosa through potential 
malignant conditions  to OSCC49. These findings of positive VEGF expression in 
normal mucosa and premalignant lesions may be suggestive of an angiogenic switch  
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from non angiogenic phenotype to an angiogenic phenotype74. Seema et al., in her 
study also showed epithelial positivity in 30% of normal cases12.   
In contrary, Denhart et al., in his study on oral and laryngeal dysplasia and squamous 
cell carcinoma suggested that normal oral epithelium expressed no VEGF while 
moderate dysplastic epithelium had a low level of VEGF expression and squamous 
cell carcinomas strongly expressed VEGF75. 
Carlilie et al., on the other hand found no difference between VEGF expression in 
normal oral mucosa when compared to epithelial dysplasia indicating that an increase 
in dysplasia is not accompanied by increase in VEGF expression7. Johnstone and 
Logan et al., in their study also found significant upregulation of VEGF during 
transition from normal oral mucosa through oral epithelial dysplasia to OSCC 
indicating that VEGF might play a significant role in angiogenesis of oral premaligant 
and malignant lesions49. However, the present study did not include cases of oral 
epithelial dysplasia. 
Gandolfo et al., in their study showed increased VEGF-A expression in areas 
adjacent to tumours and leukoplakia with dysplasia than without dysplasia. They 
concluded that expression of VEGF-A and sub-basal vascularisation could be used for 
the evaluation of severity of OPMDs and also suggested that angiogenesis is induced 
by epithelia in early stage of cancerisation. However, this study did not include cases 
of OSMF53. 
In a study by Madhavannirmal et al., in which they evaluated VEGF as a 
possible indicator in maliganant transformation of OSMF, 52.3% OSMF cases 
expressed VEGF positivity and 30% normal mucosa cases showed positivity61. In the  
Discussion 
 
present study all (100%) of OSMF cases exhibited VEGF positivity. Mukherjee et 
al., in their study in Oral Submucous Fibrosis, leukoplakia and in OSCC found a  
strong positivity of VEGF, MMP2, and MMP9 in both precancerous and cancerous 
tissue sections which was similar to observations made in our study67. 
Lalla et al., studied VEGF receptors on tumour cells in head and neck squamous cell 
carcinoma (HNSCC), and concluded that HNSCC tumour cells expressed VEGF in all 
their specimens which is also similar to the present study where all OSCC specimens 
expressed positivity.  Angiogenesis is regulated by a network of chemical signals 
(angiogenic factors) which interact with angiogenic factor receptors and they control 
growth, differentiation, and maturation of new capillaries. These receptors are present 
on tumour cells, in addition to Vascular endothelial Cells, suggesting that tumour cells 
have the ability to regulate their own growth. These complex paracrine/autocrine 
pathways interact to promote angiogenesis and uncontrolled tumour proliferation and 
also helps in regulation of metastatic processes.  Thus VEGFRs that are expressed by 
HNSCC tumour cells may indicate that VEGF is an autocrine regulator of tumour cell 
activity in addition to its known angiogenic effects on Vascular endothelial cells76.  
 
In our study, while comparing intensity of VEGF between the study groups, 
72.5% specimens exhibited mild intensity and 20 % showed moderate staining and 
7.5% specimens did not show staining at all. The staining intensity of VEGF was 
independent of the grade of tumour. The above results were consistent with the 
findings by Maeda et al., in 199877, Carlile et al., in 20017, Johnstone and Logan et  
 
Discussion 
  
al., in 200615 and Miyahara et al., in 200778. In all these studies investigators did not 
find any correlation between the VEGF staining intensity with the grade of OSCC. 
However Astekar et al., in 2012 found in their study that VEGF expression decreased 
from well differentiated to moderately differentiated to poorly differentiated OSCC79. 
Madhavannirmal et al., conducted a study on VEGF as a possible indicator in the 
malignant transformation of OSMF. They did not find any statistical significance in 
the intensity of staining. However, they made a valuable observation that a marked 
increase in VEGF secretion was evidenced when the epithelial cells breach, acquire 
epithelial – mesenchymal transition and become an invasive carcinoma61. 
Vascular endothelial growth factor has been identified as one of the prime 
factors secreted by tumour cells that stimulate existing endothelial cells to proliferate 
by paracrine mechanism and facilitates growth, invasion and metastasis of the tumour. 
Any potentially altered oral epithelium can proliferate, breach the underlying 
basement membrane and even transform into an invading carcinoma. It requires 
profuse blood supply which in turn modulates the existing blood supply and 
architecture in the stromal tissue61.  
Thus, there was increased immunohistochemical expression of VEGF-A in 
OSMF and OSCC in comparison to healthy controls suggesting that VEGF may be 
used as a useful marker in the assessment of angiogenesis in OSMF and invasive 
OSCC.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Summary and Conclusion 
                            Summary and Conclusion 
  
 
 A total of 40 biopsies were included in this study, comprising of ten cases of   
   normal oral mucosa (group I), ten cases of OSMF (group II) and twenty cases of    
   OSCC (group III).  
 In group I, all the cases were taken from from retromolar region from patients who    
   had come for removal of impacted teeth.  
 In group II, all (100%) biopsies were taken from the buccal mucosa. 
 In group III, 35% of biopsies were taken from the lateral border of the tongue,  
   30% from the buccal mucosa, 20% from the gingiva and 5% each from palate,   
   alveolar mucosa and vestibule. 
  Out of 20 cases in group III, 85% were well differentiated OSCC and 15% were  
     moderately differentiated OSCC. 
  The pattern of VEGF-A staining in all the groups was cytoplasmic.   
  All OSMF specimens showed VEGF-A positivity and in normal mucosa 70 %  
    showed 70% positivity. 
 All the cases in OSCC showed positivity. In OSCC, 65% of well differentiated    
   and 100% of moderately differentiated cases expressed mild intensity of staining.   
   About 35% of well differentiated cases expressed moderate staining intensity.   
   There was no statistically significant difference of VEGF-A expression seen in the  
   increasing grades of OSCC. 
 Our study shows increased expression of VEGF-A in basal and suprabasal layers in  
   OSMF and in all the tumour cells of OSCC indicating that VEGF expression has   
   potential to be a surrogate marker of malignant transformation.  
 
 
  Summary and Conclusion 
  
 
   In this study, we have addressed the expression of VEGF-A in a study group of Oral       
   Submucous Fibrosis and Oral Squamous Cell Carcinoma. The result of this study  
   has highlighted that, there is increased immunohistochemical expression of VEGF-  
   A in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma when compared  
  to that of normal mucosa. Thus, the analysis of VEGF-A expression before treatment  
  might be used in assessing biologic behaviours of tumours. Apart from being a part   
  of antiangiogenic therapy, VEGF-A could  also help in early detection of tumours  
  and in reducing the mortality and morbidity of oral cancer. 
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                                          DISSERTATION PROTOCOL  
1. Title of the dissertation  
Expression of Vascular Endothelial Growth Factor (VEGF-A) in Oral Submucous 
Fibrosis and Oral Squamous Cell Carcinoma - an immunohistochemistry study 
2. Name and designation of the principal investigator  
Dr. S. Siva shankari 
II year postgraduate student  
Department of Oral and Maxillofacial Pathology  
3. Name of HOD and staff in charge  
Dr. K. Ranganathan, MDS, MS (Ohio), Ph.D  
Dr. T. Rooban, MDS  
4. Department where the project is to be carried out  
Study will be conducted in Department of Oral & Maxillofacial Pathology,  
Ragas Dental College & Hospital  
5. Duration of the project  
1 year  
6. Rationale  
Vascular Endothelial Growth Factor –A (VEGF-A) is a fundamental regulator of 
tumour angiogenesis. Tissue VEGF-A can be assessed by immunohistochemistry 
using antibodies against VEGF-A on formalin fixed paraffin embedded tissue (FFPE) 
sections. 
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7. Hypothesis (null)  
There is no difference in expression of VEGF-A in Oral Submucous Fibrosis, Oral 
Squamous Cell Carcinoma when compared to normal mucosa. 
AIM  
To study the expression of Vascular Endothelial Growth Factor A (VEGF-A) in 
tissues of Oral Submucous Fibrosis (OSMF) and Oral Squamous Cell Carcinoma 
(OSCC) by immunohistochemistry (IHC). 
OBJECTIVES: 
To investigate the extent of VEGF-A expression in tissues of Oral Submucous 
Fibrosis and Oral Squamous Cell Carcinoma by Immunohistochemistry. 
8. MATERIALS AND METHODS  
Sample:  
Group I: 15 normal oral mucosal tissue specimens.  
Group II: 15 histopathologically confirmed OSMF tissue specimens.  
Group III: 15 histopathologically confirmed OSCC tissue specimens.  
Procedure:  
Immunohistochemistry (IHC)  
Statistics to be used:  
 Chi-square test  
 Data analysis to be done using SPSS (Statistical Package of Social Science)  
Version 21  
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Equipments and chemical reagents needed:  
1. Microtome  
2. Autoclave  
3. Hot air oven  
4. Slide warmer  
5. Coupling jars  
6. Measuring jar 
7. Weighing machine  
8. APES coated slides  
9. Slide carrier  
10. Aluminium foil  
11. Micro-pipettes  
12. Toothed forceps  
13. Electronic timer  
14. Beakers  
15. Rectangular steel tray with glass rods  
16. Sterile gauze  
17. Cover-slips  
18. Light microscope  
Reagents used:  
1. Conc. HCl  
2. APES (Amino propyl triethoxysilane)  
3. Acetone  
4. Tris EDTA buffer  
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5. Tris Buffered Saline (TBS)  
6. 3% H2O2  
7. Deionized distilled water  
8. Hematoxylin  
9. Absolute alcohol  
10. Xylene 
Signature of principal investigator  
Signature of Head of Department  
Remarks of committee:  
Permission granted YES/NO  
Modifications / condition 
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DEPARTMENT DECLARATION FORM 
 
 
 
The study titled “Expression of Vascular Endothelial Growth Factor (VEGF-A) in 
Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma - an 
immunohistochemistry study” have been done under the guidance of the staffs of 
Department of Oral Pathology and Microbiology during my post-graduation 
during 2015-2018. The same has been submitted as a part of the syllabus MDS degree 
programme in Oral Pathology and Microbiology of the Tamil Nadu 
Dr.M.G.R.Medical University, Chennai. 
 
             I shall publish in full or part of this work in any media with only with the 
prior written approval of the head of the department. 
 
 
 
 
 
 
 
Dr. S.Siva shankari, 
Post-graduation 2015-2018, 
Department of Oral Pathology and Microbiology, 
Ragas Dental College and Hospital, Chennai 
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                                            ANNEXURE VII 
                                    
The triggering mechanism in tumour angiogenesis: inactivated tumour 
suppressor genes/activated oncogenes versus hypoxia. 
 
 
                                                                                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumour 
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  VEGF 
PKB/Akt,MAPK,eNOS 
EC Proliferation and 
Survival 
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Ras-raf-MAPK 
Fibrin formation 
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Continued tumour growth and 
dysfunctional vasculature 
Activated oncogenes and 
/or inactivated tumour 
suppressor genes 
Progressive 
growth 
       Adapted from: Immunohistochemical Study of VEGF Expression in Oral Squamous Cell  Carcinomas: Correlation with the 
       mTOR–HIF-1α Pathway Naruse T, Kawasaki G, Yanamoto S, Mizuno A, Umeda M Anticancer research, Volume 31: 4429-4438 
       (2011) 
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Schematic diagram showing possible molecules and pathways involved in the  
pathogenesis of oral submucous fibrosis 
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ORAL SUBMUCOUS FIBROSIS 
Adapted from: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and 
inhibition of tumour angiogenesis, Rak J, Mitsuhashi Y,  Bayko L, Fitmus J, Shirasawa S, Sasazuki T, Cancer 
Research 1995; 55(20): 4575—80 
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Possible events in the malignant transformation of oral submucous fibrosis 
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Oxidative 
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DNA double strand 
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genetic damages in 
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transformation 
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Cell proliferation and 
survival 
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Reduced 
blood supply 
Senescent 
fibroblast VEGF 
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TGF-β  
Alteration of various 
oncosupressor genes 
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Adapted from: Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, leukoplakia,  
and oral submucous fibrosis, Varun BR, Ranganathan K, Rao UK, Joshua E, Journal of Investigation in Clinical 
Dentistry 2014; 52214-219.  
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Schematic diagram showing association observed in studies assessing malignant 
transformation of oral submucous fibrosis (OSMF) 
 
 
 
 
 
Increased 
Chymase/ 
tryptase 
Altered connective 
tissue matrix 
DNA damage 
Access to subepithelial 
connective tissue 
Epithelial 
shrinkage 
Areca nut/Arecoline 
Mast cells 
Angiogenesis 
Fibrosis LOX 
Myofibroblasts 
EMT 
SCC 
OSMF 
1.AgNOR increase & 
dispersion 
2.Increased micronuclei 
3.p63 expression 
4.Loss of cadherins 
Keratin protein 
alterations 
Epithelial 
Dysplasia 
With/without 
Hyperplasia 
      Adapted from: Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis,  
      tumour progression and field  cancerisation. Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Journal  
     of Oral Pathology and Medicine 2001 30: 449-457 
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                                          ANNEXURE VIII 
 
                                         ABBREVIATIONS 
1. VEGF    - Vascular Endothelial Growth Factor 
2. OSCC    - Oral squamous cell carcinoma  
3. HNSCC - Head and neck squamous cell carcinoma  
4. WHO    - World Health Organisation  
5. IHC      -  Immunohistochemistry  
6. APES    - Amino propyl triethoxysilane  
7. H&E     - Hematoxylin and Eosin  
8. LM       -  Light Microscope  
9. HCl      -  Hydrochloric acid  
10. H2O2 -  Hydrogen peroxide  
11. DAB   -  Di amino benzidine   
12. HRP   -  Horseradish Peroxidase  
13. DPX    - Dibutyl Phthalate in xylene   
14. OSMF - Oral Submucous Fibrosis 
15. VPF     - Vascular Permeability Factor 
16. INK      - Inhibitor Kinases  
17. LOH     - Loss of heterozygosity  
18. DNA     - Deoxy ribo nucleic acid  
19. EGFR  -  Epidermal Growth Factor Receptor  
20. ECM    -  Extracellular matrix 
 
Annexures 
   
21. TSG                -  Tumour suppressor gene  
22. bcl2                 -  B cell lymphoma 2 gene   
23. p53(or)TP53   - Protein 53 (or ) Tumour Protein 53  
24. EC                   - Endothelial cell 
25. VEGFR           - Vascular Endothelial Growth Factor Receptor 
26. CTGF              - Connective Tissue Growth Factor 
27. ROS                 - Reactive Oxygen Species 
28. TIMP-1           - Tissue inhibitor of metalloproteinase -1  
29. TNF-α             - Tumour necrosis factor  
30. HIF-1α            - Hypoxia inducible factor 1α  
31. MMP              - Matrix metalloproteinase 
32. EMT               - Epithelial mesenchymal transition  
33. MAPK            - Mitogen activated protein kinases  
34. TGF                - Transforming growth factor  
35. Bfgf                 - Basic Fibroblast Growth Factor  
36. CK                  - Cytokeratin 
37. iNOS               - inducible Nitric Oxide Synthase  
38. PDGF             - Platelet Derived Growth Factor                           
39. RTKs              - Receptor Tyrosine Kinases  
40. eNOS              - endothelial Nitric Oxide Synthase  
41. COX               - Cyclooxygenase  
42.MVD                - Microvessel Density 
 
 
